Header Logo

Connection

Shabir Madhi to Pneumococcal Vaccines

Back to Details
This is a "connection" page, showing publications Shabir Madhi has written about Pneumococcal Vaccines.
Shabir Madhi
Connection Strength
22,367
Pneumococcal Vaccines
  1. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,775
  2. Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
    View in: PubMed
    Score: 0,761
  3. An affordable pneumococcal conjugate vaccine after 20 years. Lancet Infect Dis. 2021 06; 21(6):751-753.
    View in: PubMed
    Score: 0,587
  4. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV. mBio. 2021 01 08; 12(1).
    View in: PubMed
    Score: 0,585
  5. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Rev Vaccines. 2020 12; 19(12):1177-1189.
    View in: PubMed
    Score: 0,583
  6. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
    View in: PubMed
    Score: 0,570
  7. Residual colonization by vaccine serotypes in rural South Africa four years following initiation of pneumococcal conjugate vaccine immunization. Expert Rev Vaccines. 2020 04; 19(4):383-393.
    View in: PubMed
    Score: 0,556
  8. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020 02 28; 38(10):2350-2360.
    View in: PubMed
    Score: 0,549
  9. Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines - Authors' reply. Lancet Infect Dis. 2019 07; 19(7):693-694.
    View in: PubMed
    Score: 0,526
  10. The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ? Lancet Infect Dis. 2019 05; 19(5):453-454.
    View in: PubMed
    Score: 0,518
  11. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,470
  12. Pneumococcal conjugate vaccines and hospitalization of children for pneumonia: a time-series analysis, South Africa, 2006-2014. Bull World Health Organ. 2017 Sep 01; 95(9):618-628.
    View in: PubMed
    Score: 0,458
  13. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial. Expert Rev Vaccines. 2017 06; 16(6):641-656.
    View in: PubMed
    Score: 0,456
  14. Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children. Expert Rev Vaccines. 2017 May; 16(5):453-465.
    View in: PubMed
    Score: 0,451
  15. Hospitalization for Culture-confirmed Pulmonary Tuberculosis in the Era of Childhood Pneumococcal Conjugate Vaccine Immunization. Pediatr Infect Dis J. 2017 01; 36(1):e14-e21.
    View in: PubMed
    Score: 0,443
  16. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine (Baltimore). 2017 Jan; 96(2):e5881.
    View in: PubMed
    Score: 0,443
  17. The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience. Hum Vaccin Immunother. 2016; 12(2):314-25.
    View in: PubMed
    Score: 0,413
  18. Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study. Thorax. 2015 Dec; 70(12):1149-55.
    View in: PubMed
    Score: 0,398
  19. Temporal Changes in Pneumococcal Colonization in HIV-infected and HIV-uninfected Mother-Child Pairs Following Transitioning From 7-valent to 13-valent Pneumococcal Conjugate Vaccine, Soweto, South Africa. J Infect Dis. 2015 Oct 01; 212(7):1082-92.
    View in: PubMed
    Score: 0,391
  20. Acquisition of Streptococcus pneumoniae in South African children vaccinated with 7-valent pneumococcal conjugate vaccine at 6, 14 and 40 weeks of age. Vaccine. 2015 Jan 29; 33(5):628-34.
    View in: PubMed
    Score: 0,385
  21. Pneumococcal conjugate vaccine and changing epidemiology of childhood bacterial meningitis. J Pediatr (Rio J). 2015 Mar-Apr; 91(2):108-10.
    View in: PubMed
    Score: 0,383
  22. Temporal association of infant immunisation with pneumococcal conjugate vaccine on the ecology of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonisation in a rural South African community. Vaccine. 2014 Sep 22; 32(42):5520-30.
    View in: PubMed
    Score: 0,375
  23. Effectiveness of pneumococcal conjugate vaccine and rotavirus vaccine introduction into the South African public immunisation programme. S Afr Med J. 2014 Mar; 104(3 Suppl 1):228-34.
    View in: PubMed
    Score: 0,364
  24. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J. 2013 Nov; 32(11):1270-8.
    View in: PubMed
    Score: 0,356
  25. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One. 2013; 8(8):e72794.
    View in: PubMed
    Score: 0,351
  26. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children. Vaccine. 2013 Sep 13; 31(40):4421-7.
    View in: PubMed
    Score: 0,348
  27. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21; 31(5):777-83.
    View in: PubMed
    Score: 0,334
  28. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. Vaccine. 2012 Sep 07; 30 Suppl 3:C21-7.
    View in: PubMed
    Score: 0,328
  29. Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination. Expert Rev Respir Med. 2012 Aug; 6(4):451-65.
    View in: PubMed
    Score: 0,326
  30. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother. 2012 Feb; 8(2):161-73.
    View in: PubMed
    Score: 0,315
  31. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine. 2011 Sep 16; 29(40):6994-7001.
    View in: PubMed
    Score: 0,304
  32. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011 Jul; 10(7):951-80.
    View in: PubMed
    Score: 0,302
  33. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis. 2010 Aug 15; 202(3):355-61.
    View in: PubMed
    Score: 0,285
  34. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009 Apr 15; 199(8):1168-76.
    View in: PubMed
    Score: 0,259
  35. Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efficacy against pneumonia and invasive disease. Vaccine. 2008 Jun 16; 26 Suppl 2:B9-B15.
    View in: PubMed
    Score: 0,245
  36. Pneumococcal conjugate vaccine--a health priority. S Afr Med J. 2008 Jun; 98(6):463-7.
    View in: PubMed
    Score: 0,244
  37. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ. 2008 May; 86(5):365-72.
    View in: PubMed
    Score: 0,243
  38. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected children. J Infect Dis. 2007 Dec 01; 196(11):1662-6.
    View in: PubMed
    Score: 0,234
  39. Pneumococcal vaccines and flu preparedness. Science. 2007 Apr 06; 316(5821):49-50.
    View in: PubMed
    Score: 0,225
  40. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007 Mar 22; 25(13):2451-7.
    View in: PubMed
    Score: 0,217
  41. World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine. 2007 Mar 22; 25(13):2413-9.
    View in: PubMed
    Score: 0,217
  42. Pneumococcal coinfection with human metapneumovirus. J Infect Dis. 2006 May 01; 193(9):1236-43.
    View in: PubMed
    Score: 0,210
  43. Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J. 2006 Jan; 25(1):30-6.
    View in: PubMed
    Score: 0,207
  44. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005 May; 24(5):410-6.
    View in: PubMed
    Score: 0,197
  45. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis. 2005 May 15; 40(10):1511-8.
    View in: PubMed
    Score: 0,196
  46. Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS Med. 2005 Feb; 2(2):e38.
    View in: PubMed
    Score: 0,195
  47. Etiologies and comorbidities of meningitis deaths in children under 5 years in high-mortality settings: Insights from the CHAMPS Network in the post-pneumococcal vaccine era. J Infect. 2024 Dec; 89(6):106341.
    View in: PubMed
    Score: 0,191
  48. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study. Lancet Glob Health. 2024 Sep; 12(9):e1470-e1484.
    View in: PubMed
    Score: 0,188
  49. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004 Aug; 10(8):811-3.
    View in: PubMed
    Score: 0,186
  50. Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis. Health Technol Assess. 2024 Jul; 28(34):1-109.
    View in: PubMed
    Score: 0,186
  51. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
    View in: PubMed
    Score: 0,184
  52. Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children. Int J Infect Dis. 2023 Sep; 134:45-52.
    View in: PubMed
    Score: 0,172
  53. Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr Infect Dis J. 2002 May; 21(5):393-9.
    View in: PubMed
    Score: 0,160
  54. High-throughput nanofluidic real-time PCR to discriminate Pneumococcal Conjugate Vaccine (PCV)-associated serogroups 6, 18, and 22 to serotypes using modified oligonucleotides. Sci Rep. 2021 12 09; 11(1):23728.
    View in: PubMed
    Score: 0,156
  55. Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ?5 years in Cameroon, 2011-2018. PLoS One. 2021; 16(4):e0250010.
    View in: PubMed
    Score: 0,149
  56. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS One. 2020; 15(1):e0227945.
    View in: PubMed
    Score: 0,137
  57. Evaluation of the impact of HIV-1 infection and density of common nasopharyngeal bacterial colonizers in South African children immunized with 7-valent pneumococcal conjugate vaccine. Vaccine. 2020 02 11; 38(7):1762-1769.
    View in: PubMed
    Score: 0,136
  58. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting. Paediatr Int Child Health. 2020 02; 40(1):50-57.
    View in: PubMed
    Score: 0,131
  59. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. J Infect. 2018 11; 77(5):368-378.
    View in: PubMed
    Score: 0,123
  60. Global Distribution of Invasive Serotype 35D Streptococcus pneumoniae Isolates following Introduction of 13-Valent Pneumococcal Conjugate Vaccine. J Clin Microbiol. 2018 07; 56(7).
    View in: PubMed
    Score: 0,123
  61. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization. Am J Epidemiol. 2017 Aug 15; 186(4):435-444.
    View in: PubMed
    Score: 0,116
  62. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017 08 03; 35(34):4321-4329.
    View in: PubMed
    Score: 0,115
  63. Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa. PLoS One. 2017; 12(7):e0179905.
    View in: PubMed
    Score: 0,115
  64. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017 03; 5(3):e359-e369.
    View in: PubMed
    Score: 0,111
  65. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV). PLoS One. 2016; 11(2):e0149104.
    View in: PubMed
    Score: 0,104
  66. Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa. BMC Infect Dis. 2015 Oct 26; 15:450.
    View in: PubMed
    Score: 0,102
  67. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015 Jul 17; 29(11):1345-54.
    View in: PubMed
    Score: 0,100
  68. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014 Nov 13; 371(20):1889-99.
    View in: PubMed
    Score: 0,095
  69. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study. Clin Infect Dis. 2014 Sep 15; 59(6):808-18.
    View in: PubMed
    Score: 0,093
  70. Radiologic diagnosis of chest infection in children: WHO end-point consolidation. Pediatr Radiol. 2014 Jun; 44(6):685-6.
    View in: PubMed
    Score: 0,092
  71. Dynamics of pneumococcal transmission in vaccine-naive children and their HIV-infected or HIV-uninfected mothers during the first 2 years of life. Am J Epidemiol. 2013 Dec 01; 178(11):1629-37.
    View in: PubMed
    Score: 0,088
  72. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine. 2013 Aug 28; 31(38):4200-8.
    View in: PubMed
    Score: 0,086
  73. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC Public Health. 2011 Apr 13; 11 Suppl 3:S26.
    View in: PubMed
    Score: 0,074
  74. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011 Apr 18; 29(18):3372-3.
    View in: PubMed
    Score: 0,074
  75. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS. 2011 Feb 20; 25(4):453-62.
    View in: PubMed
    Score: 0,074
  76. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J. 2010 Dec; 29(12):1099-04.
    View in: PubMed
    Score: 0,073
  77. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol. 2010 Apr; 39 Suppl 1:i172-85.
    View in: PubMed
    Score: 0,069
  78. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010 Jan; 17(1):134-42.
    View in: PubMed
    Score: 0,067
  79. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine. 2009 Aug 21; 27 Suppl 3:C9-C14.
    View in: PubMed
    Score: 0,066
  80. Apnea and its possible relationship to immunization in ex-premature infants. Vaccine. 2008 Jun 25; 26(27-28):3410-3.
    View in: PubMed
    Score: 0,061
  81. Herd immunity after pneumococcal conjugate vaccination. Lancet. 2007 Jul 21; 370(9583):218-219.
    View in: PubMed
    Score: 0,058
  82. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007 May 10; 25(19):3816-26.
    View in: PubMed
    Score: 0,056
  83. Pneumococcal vaccination in developing countries. Lancet. 2006 Jun 10; 367(9526):1880-2.
    View in: PubMed
    Score: 0,053
  84. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol. 2006 Jul; 36(3):215-21.
    View in: PubMed
    Score: 0,053
  85. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? Lancet Infect Dis. 2006 Mar; 6(3):150-61.
    View in: PubMed
    Score: 0,052
  86. Geographical migration and fitness dynamics of Streptococcus pneumoniae. Nature. 2024 Jul; 631(8020):386-392.
    View in: PubMed
    Score: 0,047
  87. Nanofluidic qPCR unable to detect and serotype Streptococcus pneumoniae in urine samples of hospitalized South African patients with community-acquired pneumonia. Sci Rep. 2023 12 04; 13(1):21332.
    View in: PubMed
    Score: 0,045
  88. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003 Oct 02; 349(14):1341-8.
    View in: PubMed
    Score: 0,044
  89. Optimization of a high-throughput nanofluidic real-time PCR to detect and quantify of 15 bacterial species and 92 Streptococcus pneumoniae serotypes. Sci Rep. 2023 03 21; 13(1):4588.
    View in: PubMed
    Score: 0,043
  90. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV. AIDS. 2023 07 01; 37(8):1227-1237.
    View in: PubMed
    Score: 0,043
  91. Vaccination of the HIV-1 infected child. SADJ. 2001 Dec; 56(12):610-3.
    View in: PubMed
    Score: 0,039
  92. Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors. J Infect. 2020 10; 81(4):540-548.
    View in: PubMed
    Score: 0,035
  93. A mosaic tetracycline resistance gene tet(S/M) detected in an MDR pneumococcal CC230 lineage that underwent capsular switching in South Africa. J Antimicrob Chemother. 2020 03 01; 75(3):512-520.
    View in: PubMed
    Score: 0,034
  94. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine. 2019 May; 43:338-346.
    View in: PubMed
    Score: 0,032
  95. The role of bacterial vaccines in the prevention of influenza mortality. Lancet Glob Health. 2018 12; 6(12):e1268-e1269.
    View in: PubMed
    Score: 0,032
  96. Preliminary report from the World Health Organisation Chest Radiography in Epidemiological Studies project. Pediatr Radiol. 2017 Oct; 47(11):1399-1404.
    View in: PubMed
    Score: 0,029
  97. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study. Vaccine. 2016 11 04; 34(46):5649-5655.
    View in: PubMed
    Score: 0,027
  98. Epidemiology of Serotype 1 Invasive Pneumococcal Disease, South Africa, 2003-2013. Emerg Infect Dis. 2016 Feb; 22(2):261-70.
    View in: PubMed
    Score: 0,026
  99. Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012. Pediatr Infect Dis J. 2015 Jan; 34(1):27-34.
    View in: PubMed
    Score: 0,024
  100. Economic burden of acute lower respiratory tract infection in South African children. Paediatr Int Child Health. 2012 May; 32(2):65-73.
    View in: PubMed
    Score: 0,020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.